Sanofi-Aventis - Top 10 Layoffs of 2009
Company: Sanofi-Aventis ![]()
Layoffs: 750
Scoop: Though estimates ran as high as 1,500 cuts, Sanofi revealed last month that it had eliminated 750 sales reps. Two hundred of those people will be eligible to apply for other sales jobs in the company.
Like so many other developers on this year's list, France-based Sanofi is bracing itself for the coming patent cliff. Its sleeping pill Ambien and cancer treatment Eloxatin are already facing generic competition. But the biggest blow will come in 2011 when its mega-blockbuster drug Plavix loses patent protection. There are more cuts to come; Sanofi is still in the process of reducing its oncology sales rep staff.
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

SHARE
WITH: